Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
DNA topoisomerase IV subunit
Overview
| Protein Change | Nucleotide Change | Mechanism | Organism | Resistance To | Database | Validation Status |
|---|---|---|---|---|---|---|
| P454S | - | - | Streptococcus pneumoniae | clinafloxacin|ciprofloxacin|trovafloxacinfluoroquinolones | Reslit | Candidate |
| P454A | - | - | Streptococcus pneumoniae | clinafloxacin|ciprofloxacin|trovafloxacin | Reslit | Candidate |
| P454H | - | - | Streptococcus pneumoniae | clinafloxacin|ciprofloxacin|trovafloxacin | Reslit | Candidate |
| D435N | - | Streptococcus pneumoniae, Streptococcus pseudopneumoniae, Streptococcus mitis, Streptococcus oralis | levofloxacin|clinafloxacinciprofloxacin|garenoxacin|sparfloxacin|trovafloxacinfluoroquinolones+6 more | Reslit | Candidate | |
| D475E | - | DNA topoisomerase IV subunit B ParE | Escherichia coli, E. coli | norfloxacin|ciprofloxacinciprofloxacinciprofloxacin|nalidixic acid+1 more | ReslitReference Gene Catalog | Candidate |
| I529L | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., E. coli | norfloxacin|ciprofloxacinquinolonesciprofloxacin+7 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate | |
| I460V | - | Streptococcus pneumoniae | ciprofloxacin|garenoxacin|sparfloxacin|trovafloxacinmoxifloxacin|levofloxacin|gemifloxacinfluoroquinolones+8 more | Reslit | Candidate | |
| S468F | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| S468Y | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| P394R | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| D72G | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| D87N | - | - | Pseudomonas aeruginosa, Escherichia coli | ciprofloxacin|garenoxacinfluoroquinolones | Reslit | Candidate |
| D87H | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| D87Y | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| D87G | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| A67S | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| E470D | - | - | Pseudomonas aeruginosa | ciprofloxacin|garenoxacin | Reslit | Candidate |
| E474K | - | Streptococcus pneumoniae | fluoroquinoloneslevofloxacin|ciprofloxacinofloxacin|levofloxacin+1 more | Reslit | Candidate | |
| S458P | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica, Salmonella | ciprofloxacin|nalidixic acidciprofloxacinciprofloxacin|ofloxacin|sparfloxacin|levofloxacin|moxifloxacin|gemifloxacin+2 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| V461G | - | single resistance variant, DNA topoisomerase IV subunit B ParE | Salmonella enterica, Salmonella Typhimurium, Salmonella Enteritidis | ciprofloxacinfluoroquinolonesquinolones | ReslitCard DatabaseReference Gene Catalog | Candidate |
| I460N | - | - | Streptococcus pneumoniae | moxifloxacin|levofloxacin|gemifloxacin | Reslit | Candidate |
| V461I | - | - | Streptococcus pneumoniae | moxifloxacin|levofloxacin|gemifloxacin | Reslit | Candidate |
| D420N | - | DNA topoisomerase IV subunit B ParE | Haemophilus influenzae, Salmonella, Proteus mirabilis, Escherichia coli, Salmonella Typhi, Vibrio sp. | fluoroquinolonesciprofloxacinciprofloxacin|levofloxacin+4 more | ReslitReference Gene Catalog | Candidate |
| S458A | resistance, Target modification, DNA topoisomerase IV subunit B ParE | Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, E. coli, Shigella flexneri, Klebsiella spp., Salmonella Typhimurium | fluoroquinolonesciprofloxacinenrofloxacin+11 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate | |
| S474N | - | - | Haemophilus influenzae | fluoroquinolones | Reslit | Candidate |
| D419N | - | - | Pseudomonas aeruginosa | levofloxacin | Reslit | Candidate |
| S81Y | - | - | Streptococcus pneumoniae, Streptococcus pseudopneumoniae, Streptococcus mitis, Streptococcus oralis | ciprofloxacin | Reslit | Candidate |
| S81F | - | - | Streptococcus pneumoniae, Streptococcus pseudopneumoniae, Streptococcus mitis, Streptococcus oralis | ciprofloxacin | Reslit | Candidate |
| R432S | - | - | Escherichia coli | ciprofloxacin | Reslit | Candidate |
| E460V | - | - | Escherichia coli | ciprofloxacinciprofloxacin|nalidixic acid | Reslit | Candidate |
| A473V | - | single resistance variant, DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | ciprofloxacinfluoroquinolonesquinolones | ReslitCard DatabaseReference Gene Catalog | Candidate |
| N404S | - | - | Staphylococcus epidermidis | ciprofloxacin|ofloxacin|gatifloxacin|moxifloxacinlevofloxacin|gatifloxacin|moxifloxacin|tosufloxacinfluoroquinolones | Reslit | Candidate |
| S457G | - | DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | fluoroquinolonesquinolones | ReslitReference Gene Catalog | Candidate |
| S457T | - | DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | fluoroquinolonesquinolones | ReslitReference Gene Catalog | Candidate |
| E459D | - | DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | fluoroquinolonesquinolones | ReslitReference Gene Catalog | Candidate |
| E459K | - | - | Pseudomonas aeruginosa | fluoroquinolonesciprofloxacin | Reslit | Candidate |
| S412F | - | - | Pseudomonas aeruginosa | ciprofloxacin | Reslit | Candidate |
| V199M | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| D462G | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| S492F | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| D415N | - | - | E. coli | fluoroquinolones | Reslit | Candidate |
| E412V | - | - | - | fluoroquinolones | Reslit | Candidate |
| G285S | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| D1016A | - | - | Mycoplasma mycoides | ciprofloxacin | Reslit | Candidate |
| V460G | - | - | Pseudomonas aeruginosa | ciprofloxacin | Reslit | Candidate |
| S457C | - | - | Pseudomonas aeruginosa | ciprofloxacin | Reslit | Candidate |
| I355T | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli, Klebsiella pneumoniae, E. coli | ciprofloxacinciprofloxacin|nalidixic acidnalidixic acid|ciprofloxacin+2 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| L416F | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli, Salmonella enterica, E. coli, Salmonella Typhi | ciprofloxacinciprofloxacin|levofloxacinciprofloxacin|levofloxacin|norfloxacin+6 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate | |
| S493F | - | - | Salmonella, Salmonella enterica | ciprofloxacin | Reslit | Candidate |
| S458T | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | ciprofloxacinciprofloxacin|nalidixic acidfluoroquinolones+4 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate | |
| V41I | - | - | ciprofloxacin | Reslit | Candidate | |
| A150T | - | - | ciprofloxacin | Reslit | Candidate | |
| T593S | - | - | ciprofloxacin | Reslit | Candidate | |
| E470K | - | Mycoplasma hyorhinis, Salmonella typhimurium | fluoroquinolonesciprofloxacin|norfloxacin|nalidixic acid | Reslit | Candidate | |
| R448K | - | - | Ureaplasma parvum, Ureaplasma urealyticum | fluoroquinoloneslevofloxacin|moxifloxacin | Reslit | Candidate |
| S458F | - | - | - | enrofloxacin | Reslit | Candidate |
| H518Y | - | - | - | enrofloxacin | Reslit | Candidate |
| I255T | - | - | Escherichia coli | fluoroquinolones | Reslit | Candidate |
| D435G | - | - | Streptococcus pneumoniae | levofloxacin|sparfloxacin | Reslit | Candidate |
| I493L | - | Streptococcus pneumoniae | ciprofloxacin|levofloxacin|sparfloxacin|trovafloxacinfluoroquinolones | Reslit | Candidate | |
| G405S | - | - | - | fluoroquinolones | Reslit | Candidate |
| S458L | - | DNA topoisomerase IV subunit B ParE | Shigella flexneri, Escherichia coli | fluoroquinolonesnalidixic acid|ciprofloxacinciprofloxacin|levofloxacin+1 more | ReslitReference Gene Catalog | Candidate |
| D435E | - | - | Streptococcus pneumoniae | ciprofloxacinlevofloxacin|ciprofloxacin | Reslit | Candidate |
| E401G | - | - | Salmonella enterica | ciprofloxacin | Reslit | Candidate |
| D434N | - | single resistance variant | Staphylococcus epidermidis, Staphylococcus aureus | levofloxacin|gatifloxacin|moxifloxacin|tosufloxacinfluoroquinolones | ReslitCard Database | Candidate |
| R447C | - | - | Streptococcus pneumoniae | levofloxacin | Reslit | Candidate |
| I476F | - | - | Streptococcus pneumoniae | fluoroquinolones | Reslit | Candidate |
| E486K | - | - | Clostridium perfringens | fluoroquinolones | Reslit | Candidate |
| E401K | - | - | Salmonella typhimurium | ciprofloxacinfluoroquinolones | Reslit | Candidate |
| A433T | - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate |
| S83L | - | - | - | moxifloxacin | Reslit | Candidate |
| D87E | - | - | - | moxifloxacin | Reslit | Candidate |
| D533E | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| E411K | - | - | Francisella novicida, Francisella tularensis | ciprofloxacin | Reslit | Candidate |
| I464F | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | ciprofloxacin|nalidixic acidciprofloxacin|enrofloxacinfluoroquinolones+2 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| D105G | - | - | Escherichia coli | ciprofloxacin|nalidixic acid | Reslit | Candidate |
| P439S | - | Target modification, DNA topoisomerase IV subunit B ParE | Haemophilus haemolyticus, Escherichia coli, Haemophilus influenzae, Vibrio sp. | levofloxacin|tosufloxacin|moxifloxacinnalidixic acid|ciprofloxacinquinolones | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| L502F | - | DNA topoisomerase IV subunit B ParE | Haemophilus haemolyticus, Haemophilus influenzae | levofloxacin|tosufloxacin|moxifloxacinquinolones | ReslitReference Gene Catalog | Candidate |
| H212Y | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| A725V | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| V214I | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| D596N | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| T251S | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| V270I | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| A599S | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| D740E | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| D442N | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| S784N | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| M591I | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| A641E | - | - | Haemophilus haemolyticus | levofloxacin|tosufloxacin|moxifloxacin | Reslit | Candidate |
| - | - | - | Escherichia coli | fluoroquinolones | Reslit | Candidate |
| G408S | - | - | - | nalidixic acid | Reslit | Candidate |
| D432N | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | nemonoxacin|moxifloxacin|levofloxacin|ciprofloxacinquinolones | ReslitReference Gene Catalog | Candidate |
| R444C | - | - | Staphylococcus aureus | nemonoxacin|moxifloxacin|levofloxacin|ciprofloxacin | Reslit | Candidate |
| D426N | - | - | Ureaplasma urealyticum, Ureaplasma parvum, Mycoplasma hominis | levofloxacinofloxacin|sparfloxacin | Reslit | Candidate |
| V417T | - | - | Ureaplasma urealyticum, Ureaplasma parvum | levofloxacinciprofloxacin | Reslit | Candidate |
| E468K | - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate |
| E466K | - | Mycoplasma hominis, Neisseria gonorrhoeae | ciprofloxacin|ofloxacin|sparfloxacin|trovafloxacinciprofloxacin | Reslit | Candidate | |
| L446F | - | - | Mycoplasma hominis | ofloxacin|pefloxacin | Reslit | Candidate |
| S437L | - | - | Stenotrophomonas maltophilia | ciprofloxacin | Reslit | Candidate |
| S465L | - | - | Stenotrophomonas maltophilia | ciprofloxacin | Reslit | Candidate |
| S477L | - | - | Stenotrophomonas maltophilia | ciprofloxacin | Reslit | Candidate |
| S485L | - | - | Stenotrophomonas maltophilia | ciprofloxacin | Reslit | Candidate |
| A325V | - | - | Streptococcus pneumoniae | fluoroquinolones | Reslit | Candidate |
| S79Y | - | - | Streptococcus pneumoniae | fluoroquinolones | Reslit | Candidate |
| D435V | - | - | Streptococcus pneumoniae | levofloxacin|ofloxacin|ciprofloxacin | Reslit | Candidate |
| E404K | - | - | Escherichia coli | enrofloxacin | Reslit | Candidate |
| E460D | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | ciprofloxacinciprofloxacin|nalidixic acidnalidixic acid|ciprofloxacin+1 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| L445H | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | ciprofloxacinciprofloxacin|nalidixic acidnalidixic acid|ciprofloxacin+1 more | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| P197S | - | - | Mycoplasma synoviae | enrofloxacin | Reslit | Candidate |
| V417I | - | - | Mycoplasma hominis | levofloxacin | Reslit | Candidate |
| E466Q | - | - | Escherichia coli | fluoroquinolonesciprofloxacin|nalidixic acid | Reslit | Candidate |
| R320S | - | - | Neisseria cinerea | ciprofloxacin | Reslit | Candidate |
| E461Q | - | - | Escherichia coli | fluoroquinolones | Reslit | Candidate |
| H221Y | - | - | Streptococcus agalactiae | levofloxacin | Reslit | Candidate |
| T223A | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| E459V | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| V200M | - | - | Pseudomonas aeruginosa | fluoroquinolones | Reslit | Candidate |
| G408D | - | - | Shigella flexneri | ciprofloxacin|levofloxacin | Reslit | Candidate |
| D437N | - | - | Neisseria gonorrhoeae | ciprofloxacin|garenoxacin|sitafloxacin | Reslit | Candidate |
| P456S | - | - | Neisseria gonorrhoeae | ciprofloxacin|garenoxacin|sitafloxacin | Reslit | Candidate |
| M438I | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica | nalidixic acidnalidixic acid|ciprofloxacinquinolones | ReslitResFinder DatabaseReference Gene Catalog | Candidate |
| T417V | - | - | Ureaplasma urealyticum | ciprofloxacin | Reslit | Candidate |
| E351K | - | - | Escherichia coli | ciprofloxacin | Reslit | Candidate |
| V136I | - | - | - | fluoroquinolonesciprofloxacin|levofloxacin|moxifloxacin | Reslit | Candidate |
| T172A | - | - | - | fluoroquinolonesciprofloxacin|levofloxacin|moxifloxacin | Reslit | Candidate |
| P446S | - | - | Ureaplasma parvum, Ureaplasma urealyticum | ofloxacin|ciprofloxacin|levofloxacin | Reslit | Candidate |
| D401G | - | - | Escherichia coli | ciprofloxacin | Reslit | Candidate |
| K568N | - | - | - | fluoroquinolones | Reslit | Candidate |
| I575T | - | - | - | fluoroquinolones | Reslit | Candidate |
| A463S | - | - | Mycoplasma faucium | fluoroquinolones | Reslit | Candidate |
| P424Q | - | confers resistance | Streptococcus mitis, Streptococcus pneumoniae | ciprofloxacin | Reslit | Candidate |
| E406A | - | - | Escherichia coli | nalidixic acid|ciprofloxacin | Reslit | Candidate |
| E460A | - | - | Escherichia coli | nalidixic acid|ciprofloxacin | Reslit | Candidate |
| A364V | - | - | Salmonella Typhi, Salmonella Paratyphi | ciprofloxacin | Reslit | Candidate |
| T447A | - | - | - | ciprofloxacin | Reslit | Candidate |
| S339L | - | - | - | ciprofloxacin | Reslit | Candidate |
| A365S | - | - | - | ciprofloxacin | Reslit | Candidate |
| E39K | - | - | - | ciprofloxacin|ofloxacin | Reslit | Candidate |
| R420H | - | - | - | enrofloxacin | Reslit | Candidate |
| R30C | - | - | - | ciprofloxacin|levofloxacin | Reslit | Candidate |
| H59R | - | - | - | ciprofloxacin|levofloxacin | Reslit | Candidate |
| S458E | - | - | Escherichia coli | enrofloxacin | Reslit | Candidate |
| E459Q | - | - | E. coli | enrofloxacin | Reslit | Candidate |
| S425P | - | - | E. coli | enrofloxacin | Reslit | Candidate |
| P451S | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | fluoroquinolonesquinolones | ReslitReference Gene Catalog | Candidate |
| R586W | - | - | Pseudomonas aeruginosa | ciprofloxacin | Reslit | Candidate |
| E439K | - | - | - | fluoroquinolones | Reslit | Candidate |
| S145N | - | - | non-typeable Haemophilus | levofloxacin|ciprofloxacin | Reslit | Candidate |
| G475K | - | - | Streptococcus pneumoniae | levofloxacin | Reslit | Candidate |
| T379K | - | - | Staphylococcus simulans | ciprofloxacin | Reslit | Candidate |
| N466K | - | - | Mycoplasma genitalium | ciprofloxacin|garenoxacin|moxifloxacin|gatifloxacin|sparfloxacin|tosufloxacin|levofloxacin|fleroxacin|norfloxacin|clinafloxacin|nadifloxacin|pazufloxacin | Reslit | Candidate |
| R135H | - | - | Ochrobactrum intermedium | quinolones | Reslit | Candidate |
| V237A | - | - | - | fluoroquinolones | Reslit | Candidate |
| S87F | - | Kocuria polaris, Mycoplasma synoviae | fluoroquinolones | Reslit | Candidate | |
| Q460P | - | - | Klebsiella pneumoniae | ciprofloxacin|levofloxacin|moxifloxacin | Reslit | Candidate |
| N79S | - | - | Brucella melitensis | fluoroquinolones | Reslit | Candidate |
| G238S | - | - | - | ciprofloxacin|nalidixic acid | Reslit | Candidate |
| A481T | - | - | - | levofloxacin|moxifloxacin | Reslit | Candidate |
| A481V | - | - | - | levofloxacin|moxifloxacin | Reslit | Candidate |
| S498T | - | - | Salmonella Typhi, Salmonella Paratyphi | ciprofloxacin | Reslit | Candidate |
| V560G | - | - | Salmonella Typhi, Salmonella Paratyphi | ciprofloxacin | Reslit | Candidate |
| I444S | - | - | Salmonella Typhi, Salmonella Paratyphi | ciprofloxacin | Reslit | Candidate |
| Y434S | - | - | Salmonella Typhi, Salmonella Paratyphi | ciprofloxacin | Reslit | Candidate |
| G112D | - | - | - | fluoroquinolones | Reslit | Candidate |
| G112E | - | - | - | fluoroquinolones | Reslit | Candidate |
| D18N | - | - | Streptococcus agalactiae | ciprofloxacin | Reslit | Candidate |
| I148V | - | - | Streptococcus agalactiae | ciprofloxacin | Reslit | Candidate |
| T196I | - | - | Streptococcus agalactiae | ciprofloxacin | Reslit | Candidate |
| D476N | - | Target modification, single resistance variant, DNA topoisomerase IV subunit B ParE | Vibrio cholerae, Escherichia coli | nalidixic acid|ciprofloxacinfluoroquinolonesquinolones | ReslitResFinder DatabaseCard DatabaseReference Gene Catalog | Candidate |
| S464F | - | Escherichia coli, Enterobacter cloacae, Citrobacter freundii | ciprofloxacin|nalidixic acidciprofloxacin|levofloxacin | Reslit | Candidate | |
| E215Q | - | - | - | ciprofloxacin | Reslit | Candidate |
| E488A | - | - | - | fluoroquinolones | Reslit | Candidate |
| V520A | - | - | Pseudomonas aeruginosa | ciprofloxacin | Reslit | Candidate |
| G423R | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| I444F | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | nalidixic acid|ciprofloxacinquinolonesnorfloxacin|ciprofloxacin | ResFinder DatabaseReference Gene CatalogReslit | Candidate | |
| I470M | - | Target modification, DNA topoisomerase IV subunit B ParE | Escherichia coli | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| E454G | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| H462Y | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| A499T | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| V514G | - | Target modification, DNA topoisomerase IV subunit B ParE | Salmonella enterica | nalidixic acid|ciprofloxacinquinolones | ResFinder DatabaseReference Gene Catalog | Candidate |
| M437I | - | single resistance variant, DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | fluoroquinolonesquinolones | Card DatabaseReference Gene Catalog | Candidate |
| G78S | - | single resistance variant, DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | aminocoumarin | Card DatabaseReference Gene Catalog | Candidate |
| R136G | - | single resistance variant, DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | aminocoumarin | Card DatabaseReference Gene Catalog | Candidate |
| P587S | - | single resistance variant | Staphylococcus aureus | fluoroquinolones | Card Database | Candidate |
| D434H | - | single resistance variant | Staphylococcus aureus | fluoroquinolones | Card Database | Candidate |
| E460K | - | DNA topoisomerase IV subunit B ParE | Escherichia coli | quinolones | Reference Gene Catalog | Candidate |
| G410V | - | DNA topoisomerase IV subunit B ParE | Neisseria gonorrhoeae, Neisseria meningitidis | quinolones | Reference Gene Catalog | Candidate |
| E459L | - | DNA topoisomerase IV subunit B ParE | Pseudomonas aeruginosa | quinolones | Reference Gene Catalog | Candidate |
| V521F | - | DNA topoisomerase IV subunit B ParE | Salmonella enterica | quinolones | Reference Gene Catalog | Candidate |
| D432H | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| D432V | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| D443E | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| R444S | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| N470S | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| P585S | - | DNA topoisomerase IV subunit B ParE | Staphylococcus aureus | quinolones | Reference Gene Catalog | Candidate |
| - | - | Salmonella enterica | fluoroquinolones | Reslit | Candidate | |
| E84V | - | - | ciprofloxacin | Reslit | Candidate | |
| - | - | Streptococcus pneumoniae | ciprofloxacin|levofloxacin | Reslit | Candidate | |
| N209D | - | - | ofloxacin | Reslit | Candidate | |
| - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate | |
| - | - | Salmonella enterica | fluoroquinolones | Reslit | Candidate | |
| - | - | Salmonella enterica | fluoroquinolones | Reslit | Candidate | |
| H103Y | - | Streptococcus pneumoniae | moxifloxacin|sparfloxacin|grepafloxacin | Reslit | Candidate | |
| L477M | - | Escherichia coli | ciprofloxacin | Reslit | Candidate | |
| - | - | Salmonella enterica | fluoroquinolones | Reslit | Candidate | |
| - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate | |
| D422E | - | - | quinolones | Reslit | Candidate | |
| V423F | - | - | fluoroquinolones | Reslit | Candidate | |
| - | - | Escherichia coli | ciprofloxacin|norfloxacin | Reslit | Candidate | |
| - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate | |
| - | - | Staphylococcus aureus | premafloxacin|ciprofloxacin | Reslit | Candidate | |
| - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate | |
| G486S | - | - | fluoroquinolones | Reslit | Candidate | |
| - | - | - | ciprofloxacin|levofloxacin | Reslit | Candidate | |
| E406K | - | - | fluoroquinolones | Reslit | Candidate | |
| - | - | Mycoplasma genitalium | moxifloxacin | Reslit | Candidate | |
| F571L | - | - | fluoroquinolones | Reslit | Candidate | |
| S115P | - | Streptococcus pneumoniae | ciprofloxacin | Reslit | Candidate | |
| I139R | - | - | fluoroquinolones | Reslit | Candidate | |
| V154A | - | - | ofloxacin | Reslit | Candidate | |
| - | - | - | ciprofloxacin|levofloxacin | Reslit | Candidate |
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
Unknown phenotype if I444F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if S458T or S458A occur alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if I529L occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations.
parE
Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Mutation in parE leads to quinolone resistance
Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.
Horizontal transfer of fluoroquinolone resistance genes in Streptococcus pneumoniae
Mutations in parE are associated with fluoroquinolone resistance.
Fluoroquinolone-resistant Salmonella sp. in carcasses.
Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar enteritidis: involvement of ramA and other global regulators.
Novel mutation in 5408-cip.
Salmonella serovars parE conferring resistance to fluoroquinolones; CARD accession: CARD:3003317
parE
Analysis of ciprofloxacin-resistant Salmonella strains from swine, chicken, and their carcasses in Taiwan and detection of parC resistance mutations by a mismatch amplification mutation assay PCR.
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
mutations in quinolone resistance-determining region associated with resistance to fluoroquinolones
Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
Rapid pneumococcal evolution in response to clinical interventions.
Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa.
Characterization of recombinant fluoroquinolone-resistant pneumococcus-like isolates.
Mutations in parE gene associated with fluoroquinolone resistance.
Chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms among broad-spectrum-cephalosporin-resistant Escherichia coli isolates recovered from companion animals in the USA.
Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae.
Characteristics of Quinolone Resistance in Escherichia coli Isolates from Humans, Animals, and the Environment in the Czech Republic.
Less common mutation in quinolone-resistant isolates
Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.
Identification of Major Sequence Types among Multidrug-Resistant Staphylococcus epidermidis Strains Isolated from Infected Eyes and Healthy Conjunctiva.
Resistance mechanisms and fitness of Salmonella Typhimurium and Salmonella Enteritidis mutants evolved under selection with ciprofloxacin in vitro.
The Versatile Mutational Resistome of Pseudomonas aeruginosa.
parE
A Large-Scale Whole-Genome Comparison Shows that Experimental Evolution in Response to Antibiotics Predicts Changes in Naturally Evolved Clinical Pseudomonas aeruginosa.
Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.
Snapshot Study of Whole Genome Sequences of Escherichia coli from Healthy Companion Animals, Livestock, Wildlife, Humans and Food in Italy.
A Multifactorial Approach for Surveillance of Shigella spp. and Entero-Invasive Escherichia coli Is Important for Detecting (Inter)national Clusters.
Evaluation of Fluoroquinolone Resistance in Clinical Avian Pathogenic Escherichia coli Isolates from Flanders (Belgium).
Genome-based characterization of Escherichia coli causing bloodstream infection through next-generation sequencing.
Characterization of Antimicrobial Resistance Mechanisms in Clinical Isolates of Pseudomonas aeruginosa from a Cystic Fibrosis Patient
Antibiotic tolerance, persistence, and resistance of the evolved minimal cell, Mycoplasma mycoides JCVI-Syn3B.
Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.
Mutations in parE are responsible for ciprofloxacin resistance in P. aeruginosa.
The Pheno- and Genotypic Characterization of Porcine Escherichia coli Isolates.
International High-Risk Clones Among Extended-Spectrum β-Lactamase-Producing Escherichia coli in Dhaka, Bangladesh.
Phylogenetic Analysis Reveals Distinct Evolutionary Trajectories of the Fluoroquinolones-Resistant Escherichia coli ST1193 From Fuzhou, China.
Identification of CTX-M Type ESBL E. coli from Sheep and Their Abattoir Environment Using Whole-Genome Sequencing.
Mutational Diversity in the Quinolone Resistance-Determining Regions of Type-II Topoisomerases of Salmonella Serovars.
ParE mutations are less common but contribute to ciprofloxacin resistance.
A Descriptive Analysis of Urinary ESBL-Producing-Escherichia coli in Cerdanya Hospital.
associated with ciprofloxacin resistance
Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis.
Mutations in parE associated with ciprofloxacin resistance.
Characterization of Mutations in DNA Gyrase and Topoisomerase IV in Field Strains and In Vitro Selected Quinolone-Resistant Mycoplasma hyorhinis Mutants.
In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species.
mutations in quinolone resistance determining region
Occurrence and Genomic Characterization of Clone ST1193 Clonotype 14-64 in Uncomplicated Urinary Tract Infections Caused by Escherichia coli in Spain.
Prevalence and molecular characteristics of carbapenem-resistant Escherichia coli isolated from dogs in South Korea.
Detection of antimicrobial resistance in Glaesserella parasuis in South China using whole-genome sequencing.
Antimicrobial Resistance Genotypes and Mobile Genetic Elements of Poultry-Derived Escherichia coli: A Retrospective Genomic Study from the United States.
Prevalence and genetic basis of extended-spectrum β-lactamase-producing Escherichia coli carriage in broiler farms in the United Arab Emirates.
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae.
Levofloxacin treatment failure in Haemophilus influenzae pneumonia.
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to ciprofloxacin: a case report from Cameroon.
Mutation in parE was suggested as a possible cause of reduced susceptibility to ciprofloxacin.
Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.
Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.
Comparison of the metabolic activities of four wild-type Clostridium perfringens strains with their gatifloxacin-selected resistant mutants.
Mutation in topoisomerase IV gene
Repression of invasion genes and decreased invasion in a high-level fluoroquinolone-resistant Salmonella typhimurium mutant.
Mutation in QRDR of parE contributes to fluoroquinolone resistance
Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals.
Mycoplasma genitalium Macrolide and Fluoroquinolone Resistance Detection and Clinical Implications in a Selected Cohort in New Zealand.
Emerging Treatment Options for Mycoplasma genitalium Infections
Mutations in the parE gene are associated with fluoroquinolone resistance.
Efflux Pump-Driven Antibiotic and Biocide Cross-Resistance in Pseudomonas aeruginosa Isolated from Different Ecological Niches: A Case Study in the Development of Multidrug Resistance in Environmental Hotspots.
mutations in parE contribute to fluoroquinolone resistance
Evolution of Antibiotic Resistance in Surrogates of Francisella tularensis (LVS and Francisella novicida): Effects on Biofilm Formation and Fitness.
Mutations in parE are associated with ciprofloxacin resistance.
Molecular Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Among the Pediatric Population in Qatar.
Whole-genome analyses of extended-spectrum or AmpC β-lactamase-producing Escherichia coli isolates from companion dogs in Japan.
associated with fluoroquinolone resistance
Clonal Clusters, Molecular Resistance Mechanisms and Virulence Factors of Gram-Negative Bacteria Isolated from Chronic Wounds in Ghana.
Prevalence and Characterization of Quinolone-Resistance Determinants in Escherichia coli Isolated from Food-Producing Animals and Animal-Derived Food in the Philippines.
Characterization of beta-lactam-resistant Escherichia coli from Australian fruit bats indicates anthropogenic origins.
Genome profiling of fluoroquinolone-resistant uropathogenic Escherichia coli isolates from Brazil.
Phenotypic and Genotypic Properties of Fluoroquinolone-Resistant, qnr-Carrying Escherichia coli Isolated from the German Food Chain in 2017.
Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic Escherichia coli Isolated From Female Patients in Shanghai, China.
High-Level Quinolone-Resistant Haemophilus haemolyticus in Pediatric Patient with No History of Quinolone Exposure.
Similarities in Virulence and Extended Spectrum Beta-Lactamase Gene Profiles among Cefotaxime-Resistant Escherichia coli Wastewater and Clinical Isolates.
Genomic Profiling of Antibiotic-Resistant Escherichia coli Isolates from Surface Water of Agricultural Drainage in North-Western Mexico: Detection of the International High-Risk Lineages ST410 and ST617.
Single amino acid exchange in ParE
Wild Boars as an Indicator of Environmental Spread of ESβL-Producing Escherichia coli.
Genetic and in-silico approaches for investigating the mechanisms of ciprofloxacin resistance in Salmonella typhi: Mutations, extrusion, and antimicrobial resistance.
Molecular Characterization of Multidrug-Resistant Escherichia coli from Fecal Samples of Wild Animals.
Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis.
Mutation at codon 408 in parE is associated with resistance to nalidixic acid but remains sensitive to ciprofloxacin.
Comparative In vitro antibacterial activity of nemonoxacin and other fluoroquinolones in correlation with resistant mechanisms in contemporary methicillin-resistant Staphylococcus aureus blood isolates in Taiwan.
Genomic Characterization and Antimicrobial Resistance of ESBL-Producing, Escherichia coli Isolates in Suzhou, China.
Ribosome Phenotypes Can Be Used to Classify Ciprofloxacin-Resistant Clinical E. coli Isolates
Mutation in parE leads to ciprofloxacin resistance
Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023.
In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin.
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.
Multiple mutations in parE were found in 16 of 32 strains
Mutations in Topoisomerase Genes of Fluoroquinolone-Resistant Salmonellae in Hong Kong.
Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001.
Mutations in parE contribute to fluoroquinolone resistance.
Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Ciprofloxacin-resistant Salmonella enterica serotype Typhimurium, China.
Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a Neonatal Patient in China.
Novel Levofloxacin-Resistant Multidrug-Resistant Streptococcus pneumoniae Serotype 11A Isolates, South Korea.
Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-H30Rx and ST131-H30R1 Strains.
The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations.
Mutation in quinolone resistance-determining region
Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006-2016
Characterization of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Jurong Lake, Singapore with Whole-Genome-Sequencing.
Molecular characterization of fluoroquinolone-resistant Escherichia coli from broiler breeder farms.
Mutations in parE are associated with fluoroquinolone resistance.
Antibiotic resistance of Mycoplasma Synoviae strains isolated in China from 2016 to 2019.
Whole-Genome Sequencing of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli From Human Infections in Finland Revealed Isolates Belonging to Internationally Successful ST131-C1-M27 Subclade but Distinct From Non-human Sources.
Chromosomal quinolone resistance mutations in parE
Clinical and Microbiological Characterization of Bloodstream Infections Caused by Mycoplasma hominis: An Overlooked Pathogen.
Draft Genome Sequence of a Uropathogenic Escherichia coli Sequence Type 44 Strain Carrying Multiple Antimicrobial Resistance Genes.
Whole Genome Sequence Analysis of Multidrug Resistant Escherichia coli and Klebsiella pneumoniae Strains in Kuwait.
In vitro evolution of ciprofloxacin resistance in Neisseria commensals and derived mutation population dynamics in natural Neisseria populations.
Mutations in ParE were found in various Neisseria species and associated with elevated ciprofloxacin MICs.
Eradication of Helicobacter pylori reshapes gut microbiota and facilitates the evolution of antimicrobial resistance through gene transfer and genomic mutations in the gut.
Genomic mutations in parE contributed to resistance to nalidixic acid and ciprofloxacin.
Wastewater based genomic surveillance key to population level monitoring of AmpC/ESBL producing Escherichia coli.
Prevalence and characterization of ciprofloxacin-resistant Salmonella enterica spp. isolated from food animals during 2010-2023 in South Korea.
Predomination of hypervirulent ST283 and genetic diversity of levofloxacin resistance in multidrug-resistant, hypervirulent Streptococcus agalactiae in Thailand.
Genomic insights into antimicrobial resistance and virulence of E. coli in central Ethiopia: a one health approach.
Variable In Vitro Efficacy of Delafloxacin on Multidrug-Resistant Pseudomonas aeruginosa and the Detection of Delafloxacin Resistance Determinants.
mutation in quinolone-resistance-determining region
Analyzing Shigella in Wuhan: Serotypes, Antimicrobial Resistance, and Public Health Implications.
Susceptibility of Neisseria gonorrhoeae to Zoliflodacin and Quinolones in Hyogo Prefecture, Japan.
associated with high non-susceptibility to quinolones
Molecular characterization of mcr-1.1-harboring multidrug-resistant Escherichia coli isolates from chicken in the United Arab Emirates: implications for one health surveillance.
Mutation in parE contributes to fluoroquinolone resistance
Genetic diversity of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates and the first identification of serotype 20B in China.
High resolution melting analysis for rapid mutation screening in gyrase and Topoisomerase IV genes in quinolone-resistant Salmonella enterica.
missense mutation
Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals.
'Supermutators' found amongst highly levofloxacin-resistant E. coli isolates: a rapid protocol for the detection of mutation sites.
The parE-S458A mutation was strongly associated with R/HR isolates.
Emergence of Ciprofloxacin-Resistant Salmonella enterica Serovar Typhi in Italy.
Antibiotic Susceptibility and Sequence Type Distribution of Ureaplasma Species Isolated from Genital Samples in Switzerland.
Val417Thr detected in U. parvum serovar 1 and Thr417Val detected in U. urealyticum
Next generation genome sequencing reveals phylogenetic clades with different level of virulence among Salmonella Typhimurium clinical human isolates in Hong Kong.
A role for the bacterial GATC methylome in antibiotic stress survival.
Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance.
parE
The Resistome, Mobilome, Virulome and Phylogenomics of Multidrug-Resistant Escherichia coli Clinical Isolates from Pretoria, South Africa.
Mutations in parE contribute to fluoroquinolone resistance.
Quinolone antibiotics.
Spread of multidrug resistance among Ureaplasma serovars, Tunisia.
Genomic Characterization of Antibiotic Resistant Escherichia coli Isolated From Domestic Chickens in Pakistan.
Population Bottlenecks Strongly Influence the Evolutionary Trajectory to Fluoroquinolone Resistance in Escherichia coli.
Mutation in drug target gene
Comparative analysis of multidrug resistance plasmids and genetic background of CTX-M-producing Escherichia coli recovered from captive wild animals.
Mutations in quinolone resistance-determining region
Resistome, mobilome, and virulome explored in clinical isolates derived from acne patients in Egypt: unveiling unique traits of an emerging coagulase-negative Staphylococcus pathogen.
Prevalence and molecular characterization of multi-resistant Escherichia coli isolates from clinical bovine mastitis in China.
Genomic characterization of extended-spectrum beta-lactamase-producing and carbapenem-resistant Escherichia coli from urban wastewater in Australia.
Fluoroquinolone resistance in complicated urinary tract infections: association with the increased occurrence and diversity of Escherichia coli of clonal complex 131, together with ST1193.
Mutation associated with fluoroquinolone resistance
Genomic analysis of Salmonella isolated from canal water in Bangkok, Thailand.
Short reads-based characterization of pathotype diversity and drug resistance among Escherichia coli isolated from patients attending regional referral hospitals in Tanzania.
The complete genome sequence of unculturable Mycoplasma faucium obtained through clinical metagenomic next-generation sequencing.
This mutation was previously reported in two M. hominis strains.
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
A novel sense mutation affecting the ParE subunit
Quinolone resistance mechanisms among extended-spectrum beta-lactamase (ESBL) producing Escherichia coli isolated from rivers and lakes in Switzerland.
Two novel mutations in parE among Shigella flexneri isolated from Jiangsu Province of China, 2016.
The mutation Ser458Leu was found in 2 isolates and conferred resistance to nalidixic acid and ciprofloxacin.
Resolution of fluoroquinolone-resistant Escherichia coli keratitis with a PROSE device for enhanced targeted antibiotic delivery.
Salmonella enterica Serovar Typhi in Bangladesh: Exploration of Genomic Diversity and Antimicrobial Resistance.
Mutations in parE are associated with ciprofloxacin resistance.
The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa.
Mutations in QRDR
Mycoplasmas under experimental antimicrobial selection: The unpredicted contribution of horizontal chromosomal transfer.
Persistence and Microevolution of Pseudomonas aeruginosa in the Cystic Fibrosis Lung: A Single-Patient Longitudinal Genomic Study.
Mutations in parE are associated with fluoroquinolone resistance
Resistance and Virulence Mechanisms of Escherichia coli Selected by Enrofloxacin in Chicken
Prevalence and mechanism of fluoroquinolone resistance in clinical isolates of Proteus mirabilis in Japan.
Effects of a previously selected antibiotic resistance on mutations acquired during development of a second resistance in Escherichia coli.
Mutations in parE were observed in wild-type E. coli adapted to enrofloxacin.
In Vitro and In Vivo Activity of Zabofloxacin and Other Fluoroquinolones Against MRSA Isolates from A University Hospital in Egypt.
Isolation of extended-spectrum β-lactamase-producing Escherichia coli from Japanese red fox (Vulpes vulpes japonica).
Genetic Predictive Factors for Nonsusceptible Phenotypes and Multidrug Resistance in Expanded-Spectrum Cephalosporin-Resistant Uropathogenic Escherichia coli from a Multicenter Cohort: Insights into the Phenotypic and Genetic Basis of Coresistance.
Detection and characterization of ESBL-producing Escherichia coli and additional co-existence with mcr genes from river water in northern Thailand.
Parallel Evolution to Elucidate the Contributions of PA0625 and parE to Ciprofloxacin Sensitivity in Pseudomonas aeruginosa.
The ParE R586W substitution does not contribute to resistance but confers tolerance against ciprofloxacin.
One health clones of multidrug-resistant Escherichia coli carried by synanthropic animals in Brazil.
An ST131 clade and a phylogroup A clade bearing an O101-like O-antigen cluster predominate among bloodstream Escherichia coli isolates from South-West Nigeria hospitals.
Mutations in parE contribute to fluoroquinolone resistance.
Quinolone-resistant Escherichia coli at the interface between humans, poultry and their shared environment- a potential public health risk.
Single substitution
Fluoroquinolone resistance among fecal extended spectrum βeta lactamases positive Enterobacterales isolates from children in Dar es Salaam, Tanzania.
Discovery of a novel sub-lineage of multi-drug resistant Shigella flexneri in Southern California.
chromosomal mutation
Genome profiling of uropathogenic E. coli from strictly defined community-acquired UTI in paediatric patients: a multicentric study.
Genomic Characterization of Uropathogenic Escherichia coli Isolates from Tertiary Hospitals in Riyadh, Saudi Arabia.
Current State of Knowledge Regarding WHO High Priority Pathogens-Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review.
mutations in the parE gene confer resistance to fluoroquinolones in N. gonorrhoeae
Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone.
mutations in QRDR of parE contribute to fluoroquinolone resistance
Molecular characterization of multidrug-resistant non-typeable Haemophilus influenzae with high-level resistance to cefuroxime, levofloxacin, and trimethoprim-sulfamethoxazole.
Serotype replacement and an increase in non-encapsulated isolates among community-acquired infections of Streptococcus pneumoniae during post-vaccine era in Japan.
Multidrug Resistance Profiles and Resistance Mechanisms to β-Lactams and Fluoroquinolones in Bacterial Isolates from Hospital Wastewater in Bangladesh.
Species Profiles and Antimicrobial Resistance of Non-aureus Staphylococci Isolated from Healthy Broilers, Farm Environments, and Farm Workers.
Fluoroquinolone resistance determinants in carbapenem-resistant Escherichia coli isolated from urine clinical samples in Thailand.
most common mutation
Molecular epidemiology and pathogenomics of extended-spectrum beta-lactamase producing- Escherichia coli and - Klebsiella pneumoniae isolates from bulk tank milk in Tennessee, USA.
Mutation in parE contributes to fluoroquinolone resistance.
Escherichia coli sequence type 410 with carbapenemases: a paradigm shift within E. coli toward multidrug resistance.
associated with fluoroquinolone resistance
parE
Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.
Acquired genetic mechanisms of a multiresistant bacterium isolated from a treatment plant receiving wastewater from antibiotic production.
Mutations in quinolone target genes
Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014).
First Occurrence of OXA-72-Producing Acinetobacter baumannii in Serbia.
Mutations in gyrA and parC have previously been shown to be responsible for resistance to fluoroquinolones in Acinetobacter species
Genome Sequence of Kocuria polaris Strain CD08_4, an Isolate from the Duodenal Mucosa of a Celiac Disease Patient.
Exploring the Genome and Phenotype of Multi-Drug Resistant Klebsiella pneumoniae of Clinical Origin.
Chromosomal mutations that accompany qnr in clinical isolates of Escherichia coli.
Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy.
Mutation in the QRDR of parE contributes to fluoroquinolone resistance.
Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective.
Mutation in parE was not associated with fluoroquinolone resistance as determined by phenotypic testing.
Emergence of CTX-M-27-producing Escherichia coli of ST131 and clade C1-M27 in an impacted ecosystem with international maritime traffic in South America.
Phylogenetic Grouping of Human Ocular Escherichia coli Based on Whole-Genome Sequence Analysis.
Antimicrobial Resistance in Clinical Ureaplasma spp. and Mycoplasma hominis and Structural Mechanisms Underlying Quinolone Resistance.
mutations in ParE are associated with quinolone resistance
Discovery of seven novel mutations of gyrB, parC and parE in Salmonella Typhi and Paratyphi strains from Jiangsu Province of China.
Mutations in parE contribute to quinolone resistance
Genomic profiling of antimicrobial resistance genes in clinical isolates of Salmonella Typhi from patients infected with Typhoid fever in India.
Comparative Genome Analyses of Wild Type- and Quinolone Resistant Escherichia coli Indicate Dissemination of QREC in the Norwegian Broiler Breeding Pyramid.
Whole Genome Sequencing and Characterization of Multidrug-Resistant (MDR) Bacterial Strains Isolated From a Norwegian University Campus Pond.
Identification of Antimicrobial Resistance-Associated Genes through Whole Genome Sequencing of Mycoplasma bovis Isolates with Different Antimicrobial Resistances.
Multidrug-Resistant Streptococcus agalactiae Strains Found in Human and Fish with High Penicillin and Cefotaxime Non-Susceptibilities.
Unique mutations not previously reported
The prevalence and mechanism of fluoroquinolone resistance in Escherichia coli isolated from swine farms in China.
Mutations in the QRDR region
Complete Genome Assembly of a Multidrug-Resistant New Delhi Metallo-β-Lactamase 1 (NDM-1)-Producing Escherichia coli Human Isolate from a New Zealand Hospital.
Prediction of Antibiotic Susceptibility Profiles of Vibrio cholerae Isolates From Whole Genome Illumina and Nanopore Sequencing Data: CholerAegon.
The D476N mutation in parE was found in all 80 isolates, but it was not sufficient to confer resistance to NA and CIP in approximately one-quarter of the isolates.
Within-farm dynamics of ESBL-producing Escherichia coli in dairy cattle: Resistance profiles and molecular characterization by long-read whole-genome sequencing.
Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa.
mutation in parE contributes to ciprofloxacin resistance
Prevalence of Plasmid-Mediated Quinolone Resistance (PMQRs) Determinants and Whole Genome Sequence Screening of PMQR-Producing E. coli Isolated from Men Undergoing a Transrectal Prostate Biopsy.
Genomic characterization of two metagenome-assembled genomes of Tropheryma whipplei from China.
Acquisition of genomic elements were pivotal for the success of Escherichia coli ST410
Keeping up with the pathogens: improved antimicrobial resistance detection and prediction from Pseudomonas aeruginosa genomes.
missense mutation
Prevalence and Mechanism of Fluoroquinolone Resistance in Escherichia coli Isolated from Swine Feces in Korea.
Unknown phenotype if I355T occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Patterns of mutations in target genes in septicemia isolates of Escherichia coli and Klebsiella pneumoniae with resistance or reduced susceptibility to ciprofloxacin.
Unknown phenotype if L416F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if E460D occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if I464F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
parE
Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark.
Unknown phenotype if G423R occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if P439S occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Unknown phenotype if I470M occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.
parE
Avoiding perforation during endodontic access.
Unknown phenotype if S458T or S458A occur alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Characterisation of novel mutations involved in quinolone resistance in Escherichia coli isolated from imported shrimp.
Unknown phenotype if D476N occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations
Escherichia coli parE conferring resistance to fluoroquinolones; CARD accession: CARD:3003316
Quinolone Resistance Mechanisms Among Salmonella enterica in Malaysia.
parE
Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica.
Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.
Pseudomonas aeruginosa parE conferring resistance to fluoroquinolones; CARD accession: CARD:3003685
parE
Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus.
Staphylococcus aureus parE conferring resistance to aminocoumarin; CARD accession: CARD:3003314
Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin.
Staphylococcus aureus parE conferring resistance to fluoroquinolones; CARD accession: CARD:3003315
parE
Contribution of amino acid substitutions in ParE to quinolone resistance in Haemophilus haemolyticus revealed through a horizontal transfer assay using Haemophilus influenzae.
parE
Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae.
parE
Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments.
parE
Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
parE
A multiplex single nucleotide polymorphism typing assay for detecting mutations that result in decreased fluoroquinolone susceptibility in Salmonella enterica serovars Typhi and Paratyphi A.
Mutations in parE are associated with decreased fluoroquinolone susceptibility.
Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae clone.
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Mutation detected in quinolone-resistant strains
Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006.
Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
The wild-type parE gene does not confer resistance on its own, but mutations in it contribute to fluoroquinolone resistance.
Population snapshot of the extended-spectrum β-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital.
Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
Unraveling the adaptive strategies of Mycoplasma hominis through proteogenomic profiling of clinical isolates.
Mutations in ParE are associated with reduced susceptibility to ofloxacin in clinical isolates.
Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates.
ATP-bound conformation of topoisomerase IV: a possible target for quinolones in Streptococcus pneumoniae.
The His103Tyr mutation was found to confer resistance to fluoroquinolones when associated with a mutation in the QRDR of GyrA.
Mechanisms of quinolone resistance in Escherichia coli isolated from companion animals, pet-owners, and non-pet-owners.
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.
Unveiling the microevolution of antimicrobial resistance in selected Pseudomonas aeruginosa isolates from Egyptian healthcare settings: A genomic approach.
Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin.
Mutations in parE are associated with fluoroquinolone resistance
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
Mutations in parE were identified in WHO reference strains and contributed to ciprofloxacin resistance.
Quinolone resistance due to reduced target enzyme expression.
The mutation reduces the expression of ParE, leading to quinolone resistance.
Antimicrobial Resistance of Non-Typhoid Salmonella in Meat and Meat Products.
Genomic Analysis of Multidrug-Resistant Escherichia coli Strains Isolated in Tamaulipas, Mexico.
Phylogenomic Investigation of Increasing Fluoroquinolone Resistance among Belgian Cases of Shigellosis between 2013 and 2018 Indicates Both Travel-Related Imports and Domestic Circulation.
Mutation in parE is associated with ciprofloxacin resistance.
The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium.
Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Mutation in parE contributes to fluoroquinolone resistance in Streptococcus pneumoniae.
Transferable Extended-Spectrum β-Lactamase (ESBL) Plasmids in Enterobacteriaceae from Irrigation Water.